Literature DB >> 23636796

Association between FAS-1377 G/A polymorphism and susceptibility to gastric cancer: evidence from a meta-analysis.

Zhiming Wu1, Huangen Wang, Xiufeng Chu, Jiang Chen, Shengyang Fang.   

Abstract

Previous studies published to evaluate the association between FAS-1377 G/A polymorphism and susceptibility to gastric cancer provided inconclusive outcomes. To derive a more precise estimation on this association, a meta-analysis of published case-control studies was performed. Eligible studies up to November 13, 2012 were identified from PubMed, Wanfang Medicine database, and Web of Science. Nine studies with a total of 2,086 cases and 2,701 controls were finally included into this meta-analysis. Overall, there was an obvious association between FAS-1377 G/A polymorphism and susceptibility to gastric cancer (for AA versus GG: odds ratio (OR) = 1.38; 95 % confidence interval (CI) 1.00-1.91, P = 0.05; for AA versus GA/GG: OR = 1.28; 95 %CI 1.07-1.53, P = 0.006). After excluding studies with low quality, there was no between-study heterogeneity, and there was still an obvious association between FAS-1377 G/A polymorphism and susceptibility to gastric cancer (for AA versus GG: OR = 1.25; 95 %CI 1.02-1.52, P = 0.03; for AA versus GA/GG: OR = 1.27; 95 %CI 1.05-1.53, P = 0.01). Subgroup analyses by ethnicity showed that the association above was still obvious in Asians, but the association was still unclear in Caucasians owing to the limited sample. In summary, this meta-analysis suggests that the FAS-1377 G/A polymorphism is associated with susceptibility to gastric cancer, especially in Asians. More studies from Caucasians are needed to provide further evidence for the possible association in Caucasians.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23636796     DOI: 10.1007/s13277-013-0747-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

Review 1.  A vision of cell death: Fas ligand and immune privilege 10 years later.

Authors:  Thomas A Ferguson; Thomas S Griffith
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

2.  Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma.

Authors:  Rong-Miao Zhou; Na Wang; Zhi-Feng Chen; Ya-Nan Duan; Dong-Lan Sun; Yan Li
Journal:  J Gastroenterol Hepatol       Date:  2010-01-13       Impact factor: 4.029

Review 3.  Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.

Authors:  Linda M Dong; John D Potter; Emily White; Cornelia M Ulrich; Lon R Cardon; Ulrike Peters
Journal:  JAMA       Date:  2008-05-28       Impact factor: 56.272

4.  Interaction effects between genes involved in the AKT signaling pathway and phytoestrogens in gastric carcinogenesis: a nested case-control study from the Korean Multi-Center Cancer Cohort.

Authors:  Jae Jeong Yang; Lisa Y Cho; Kwang-Pil Ko; Seung Hyun Ma; Aesun Shin; Bo Youl Choi; Dong Soo Han; Kyu Sang Song; Yong Sung Kim; Soung-Hoon Chang; Hai-Rim Shin; Daehee Kang; Keun-Young Yoo; Sue K Park
Journal:  Mol Nutr Food Res       Date:  2012-10-05       Impact factor: 5.914

5.  FASL-844 T/C polymorphism: a biomarker of good prognosis of breast cancer in the Tunisian population.

Authors:  Wijden Mahfoudh; Noureddine Bouaouina; Sallouha Gabbouj; Lotfi Chouchane
Journal:  Hum Immunol       Date:  2012-06-22       Impact factor: 2.850

Review 6.  Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers.

Authors:  JeanMarie Houghton; Timothy C Wang
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

7.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

Review 8.  Helicobacter pylori and gastric cancer: factors that modulate disease risk.

Authors:  Lydia E Wroblewski; Richard M Peek; Keith T Wilson
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

9.  Associations of non-metastatic cells 1 gene polymorphisms with lymph node metastasis risk of gastric cancer in Northern Chinese population.

Authors:  Ai-Lin Li; Xin Zhou; Zhen-Ning Wang; Yong-Xi Song; Peng Gao; Yuan Miao; Jin-Liang Zhu; Hui-Mian Xu
Journal:  Tumour Biol       Date:  2012-08-19

10.  Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians.

Authors:  Juozas Kupcinskas; Thomas Wex; Jan Bornschein; Michael Selgrad; Marcis Leja; Elona Juozaityte; Gediminas Kiudelis; Laimas Jonaitis; Peter Malfertheiner
Journal:  BMC Med Genet       Date:  2011-08-24       Impact factor: 2.103

View more
  5 in total

1.  CD95 rs1800682 polymorphism and cervical cancer risk: evidence from a meta-analysis.

Authors:  Yan Zhang; Shengchun Tong; Lihua Guan; Fei Na; Wei Zhao; Li Wei
Journal:  Tumour Biol       Date:  2013-10-11

2.  Quantitative assessment of the associations between DNA repair gene XRCC3 Thr241Met polymorphism and gastric cancer.

Authors:  Zhe Wang; Xu Chen; Bo Liu; Shide Li; Mingjun Liu; Hong Xue
Journal:  Tumour Biol       Date:  2013-10-03

3.  Genomic variants in Fas-mediated apoptosis pathway predict a poor response to Platinum-based Chemotherapy for Chinese Gastric Cancer Patients.

Authors:  Tingting Zhao; Wei Li; Jinfei Chen; Weisong Qin
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

4.  Associations between Fas/FasL polymorphisms and susceptibility to cervical cancer: a meta-analysis.

Authors:  Guo-qing Wang; Lei Bao; Xi-xia Zhao; Jun Zhang; Ke-jun Nan
Journal:  Tumour Biol       Date:  2013-12-28

5.  MCPerm: a Monte Carlo permutation method for accurately correcting the multiple testing in a meta-analysis of genetic association studies.

Authors:  Yongshuai Jiang; Lanying Zhang; Fanwu Kong; Mingming Zhang; Hongchao Lv; Guiyou Liu; Mingzhi Liao; Rennan Feng; Jin Li; Ruijie Zhang
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.